Pricing Log in Create free account

ImmuCell Corporation (ICCC) vs Neumora Therapeutics, Inc. (NMRA)

ImmuCell Corporation and Neumora Therapeutics, Inc. are both Biotechnology companies. ImmuCell Corporation and Neumora Therapeutics, Inc. are of similar size ($90.2M and $88.6M). Neumora Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 114×. ImmuCell Corporation has the higher net margin (2.57% vs 0.00%) and the higher return on invested capital (7.84% vs 0.00%). Across the 14 metrics below, ImmuCell Corporation leads on 12 and Neumora Therapeutics, Inc. on 2.

Valuation

Metric ICCC NMRA Biotechnology median
P/E 114.07 n/m 8.68
P/S 2.85 n/m 10.29
P/B 2.79 2.00 2.40
Price to free cash flow 20.67 n/m 20.52
EV/EBITDA 13.82 n/m 0.68
EV/Sales 2.83 n/m 10.15
Earnings yield 0.88% (256.25%) (28.86%)
Free cash flow yield 4.84% (202.88%) (22.44%)

Profitability

Metric ICCC NMRA Biotechnology median
Gross margin 40.32% 0.00% 65.16%
Operating margin 12.60% 0.00% 0.00%
Net margin 2.57% 0.00% 0.00%
Free cash flow margin 13.79% 0.00% 0.00%
Return on equity 2.57% (187.11%) (56.66%)
Return on assets 1.69% (121.89%) (49.22%)
Return on invested capital 7.84% 0.00% 0.00%

Growth

Metric ICCC NMRA Biotechnology median
Revenue growth (TTM) 8.49% — 5.64%
EPS growth (last fiscal year) 53.85% 5.23% 30.08%
Revenue growth, 5-year CAGR 12.50% — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ICCC NMRA Biotechnology median
Debt to equity 0.26 1.19 0.00
Current ratio 4.75 4.50 4.72
Net debt to EBITDA 1.19 0.53 0.96

Dividend

Metric ICCC NMRA Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric ICCC NMRA Biotechnology median
Market cap 88.55m 90.15m 150.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack